Avalo Therapeutics, Inc. (AVTX)

Develops targeted therapeutics for the treatment of rare and underserved autoimmune and rare diseases.

AVTX Stock Quote

Company Report

Avalo Therapeutics, Inc., a pioneering clinical-stage precision medicine company headquartered in Rockville, Maryland, is dedicated to discovering, developing, and commercializing targeted therapeutics for patients facing unmet clinical needs in immunology, immuno-oncology, and rare genetic diseases. The company's innovative pipeline includes AVTX-002, a fully human anti-LIGHT monoclonal antibody currently in Phase II clinical trials. This therapeutic is being evaluated for its potential in treating non-eosinophilic asthma, inflammatory bowel disease (including moderate to severe Crohn's disease and ulcerative colitis), and is also undergoing Phase III trials for COVID-19 acute respiratory distress syndrome.

Avalo Therapeutics is also advancing AVTX-007, another promising candidate in its portfolio. AVTX-007 is a fully human anti-IL-18 monoclonal antibody currently undergoing Phase I clinical trials for conditions such as still's disease, which includes adult-onset still's disease and systemic juvenile idiopathic arthritis. Additionally, the company is making significant strides in rare genetic diseases with products like AVTX-801 and AVTX-803. AVTX-801, a D-galactose substrate replacement therapy, is in Phase III trials for phosphoglucomutase 1 deficiency (PGM1), known as PGM1-CDG. AVTX-803, a L-fucose substrate replacement therapy, is also in Phase III trials for LADII, also known as SLC35C1-CDG.

Originally known as Cerecor Inc., Avalo Therapeutics rebranded in August 2021 to reflect its strategic focus and expanded therapeutic portfolio. Founded in 2011, Avalo Therapeutics has rapidly emerged as a leader in precision medicine, leveraging its expertise in molecular targeting to advance therapies that have the potential to transform treatment outcomes for patients globally.

AVTX EPS Chart

AVTX Revenue Chart

Stock Research

TBMC AEZS ALRM SIEB SBFG PNFP STX

AVTX Chart

View interactive chart for AVTX

AVTX Profile

AVTX News

Analyst Ratings